Savara (NASDAQ:SVRA) Rating Reiterated by JMP Securities

Savara (NASDAQ:SVRA)‘s stock had its “market outperform” rating restated by JMP Securities in a research report issued on Monday, Benzinga reports. They currently have a $8.00 target price on the stock. JMP Securities’ target price points to a potential upside of 52.09% from the company’s current price.

Separately, Piper Sandler increased their price target on shares of Savara from $7.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $8.20.

Savara Stock Up 6.3 %

NASDAQ SVRA opened at $5.26 on Monday. Savara has a 12 month low of $1.83 and a 12 month high of $5.70. The company has a current ratio of 15.66, a quick ratio of 15.66 and a debt-to-equity ratio of 0.19. The stock has a market cap of $726.83 million, a PE ratio of -15.94 and a beta of 0.73. The stock’s 50 day moving average is $4.89 and its 200 day moving average is $4.51.

Savara (NASDAQ:SVRA) last released its earnings results on Thursday, March 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. Research analysts predict that Savara will post -0.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Savara

A number of institutional investors have recently modified their holdings of the stock. Susquehanna Fundamental Investments LLC purchased a new position in Savara during the 1st quarter worth $394,000. Swiss National Bank purchased a new stake in Savara in the first quarter worth about $732,000. Jennison Associates LLC increased its position in Savara by 0.3% during the 1st quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock valued at $44,033,000 after purchasing an additional 26,613 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Savara by 92.3% in the 1st quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company’s stock valued at $366,000 after purchasing an additional 35,269 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Savara by 66.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 26,035 shares of the company’s stock worth $130,000 after purchasing an additional 10,381 shares during the period. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.